Clinical Case Reports, 2020 We experienced two cases of dipeptidyl peptidase‐4 (DPP‐4) inhibitor‐associated bullous pemphigoid (BP) showing an unfavorable course despite its discontinuation.
Yasutake Shinohara +8 more
doaj +1 more source
Characterization of Schnurri : an integral component of the Dpp-signaling pathway in "Drosophila melanogaster" [PDF]
, 2004 Signaling by the transforming growth factor-β (TGF-β) family of ligands plays a crucial role during development and tissue homeostasis in all multicellular organisms. The signal transduction pathway is highly conserved and relatively simple.
Hartmann, Britta
core +1 more source
The effects of dipeptidyl peptidase-4 on cardiac fibrosis in pressure overload-induced heart failure
Journal of Pharmacological Sciences, 2017 Dipeptidyl peptidase-4 (DPP-4) inhibitors are hypoglycemic agents. DPP-4 inhibitor has cardioprotective effects after transverse aortic constriction (TAC), but role of DPP-4 on cardiac fibrosis after TAC is not well known.
Masanori Hirose +6 more
doaj +1 more source
Clinical Characteristics and Metabolic Predictors of Rapid Responders to Dipeptidyl Peptidase-4 Inhibitor as an Add-on Therapy to Sulfonylurea and Metformin [PDF]
Diabetes & Metabolism Journal, 2015 BackgroundDipeptidyl peptidase-4 (DPP-4) inhibitor add-on therapy is a new option for patients with inadequately controlled type 2 diabetes who are taking combined metformin and sulfonylurea (SU).
Ye An Kim +9 more
doaj +1 more source
Frontiers in Endocrinology, 2021 AimAt present, daily DPP-4 inhibitors are quite frequently prescribed in subjects with type 2 diabetes mellitus (T2DM). Recently, it has been drawing much attention that once-weekly incretin-based injection dulaglutide was developed.
Junpei Sanada +14 more
doaj +1 more source
DPP-4 inhibitor therapy and bone fractures in people with Type 2 diabetes - A systematic review and meta-analysis. [PDF]
, 2016 AIM: Fracture risk is higher in older adults with Type 2 diabetes mellitus (T2DM). Oral glucose-lowering medications have different effects on bone metabolism. The purpose of this study is to appraise the evidence from literature and determine the effect
Marlin, Carol +4 more
core +1 more source
Linagliptin, a selective DPP-4 inhibitor, inhibits DPP-4, increases incretin levels, lowers glucagon, and improves glycaemic control in patients with Type 2 diabetes. [PDF]
, 2012 Linagliptin is a xanthine-based dipeptidyl peptidase (DPP)-4 inhibitor that is now available in numerous countries worldwide for the treatment of type 2 diabetes mellitus (T2DM). The aim of this study was to evaluate further the mechanisms underlying the
Rauch, Thomas +14 more
core +1 more source
Regulation of Dpp target genes by Mad/Medea and Brinker [PDF]
, 2009 The TGF-β family member Decapentaplegic (Dpp) is a key regulator of patterning and growth in development of Drosophila. Binding of Dpp to its receptors triggers the activation of the intracellular Smad pathway.
Weiss, Alexander
core +1 more source
DPP-IV Inhibitor–Associated Angioedema in Patient With Known History of ACE Inhibitor Angioedema [PDF]
, 2021 The patient is a 69-year-old male with a past medical history of intellectual disability, hypertension, type 2 diabetes mellitus, and angiotensin-converting enzyme (ACE) inhibitor–associated angioedema who presented to the emergency department with ...
Ejikeme, Chidinma +9 more
core +1 more source
Dipeptidyl-peptidase-4 (DPP-4) inhibitor ameliorates 5-flurouracil induced intestinal mucositis
BMC Cancer, 2019 Background Chemotherapy-induced alimentary mucositis (AM) is difficult to prevent and treatment is rarely effective. Recent study have been showed that glucagon-like peptide (GLP)-1 and GLP-2 has protective in chemotherapy-induced AM.
Jung Min Lee +12 more
doaj +1 more source